Skip to main content
. 2016 Mar 30;17(5):546–557. doi: 10.1080/15384047.2016.1167292

Figure 2.

Figure 2.

Effect of a cardiac glycoside, Digitoxigenin, on GBM and non-malignant cell viability. Cell viability detection after 24 hours of Digitoxigenin and/or TRAIL addition. (A) The effect of different doses of Digitoxigenin and TRAIL combinations on U87MG. (B) The chosen dose combination of 500 nM Digitoxigenin and 50 ng/ml TRAIL on BJ and NHA. (C) Low doses of Digitoxigenin (1–50 nM) tested on a panel of human fibroblasts: KUFibro4, KUFibro5, KUFibroMNG, BJ and Human Astrocytes (NHA). (D) Doses up to 10 nM were combined with 50 and 100 ng/ml TRAIL on BJ cells. (E) Low dose combination of Digitoxigenin on U87MG cells. * indicates p <0.05 and ns indicates nonsignificant (p>0.05).